CJC-1295 Ipamorelin is a specific therapeutic combination of two synthetic peptides used clinically to stimulate the body’s natural production and pulsatile release of Growth Hormone (GH). CJC-1295 is a Growth Hormone Releasing Hormone (GHRH) analog that extends its half-life, while Ipamorelin is a Growth Hormone Releasing Peptide (GHRP) that mimics ghrelin’s action. The synergistic effect of these two peptides results in a more sustained and physiological release of GH.
Origin
These peptides are products of modern pharmaceutical and endocrinological research aimed at developing secretagogues that safely enhance endogenous GH secretion. CJC-1295 was developed to be a long-acting version of GHRH, and Ipamorelin was synthesized as a highly selective GHRP with minimal impact on cortisol or prolactin release. Their combined use reflects a clinical strategy to mimic the body’s natural GH pulse.
Mechanism
CJC-1295 binds to the GHRH receptors on the pituitary gland, stimulating the synthesis and release of GH. Simultaneously, Ipamorelin selectively binds to the ghrelin receptor, also known as the Growth Hormone Secretagogue Receptor (GHSR), triggering a robust GH release from the pituitary. This dual action amplifies the release of GH, which subsequently travels to the liver to stimulate the production of Insulin-like Growth Factor 1 (IGF-1), mediating many of the anabolic and regenerative effects.
We use cookies to personalize content and marketing, and to analyze our traffic. This helps us maintain the quality of our free resources. manage your preferences below.
Detailed Cookie Preferences
This helps support our free resources through personalized marketing efforts and promotions.
Analytics cookies help us understand how visitors interact with our website, improving user experience and website performance.
Personalization cookies enable us to customize the content and features of our site based on your interactions, offering a more tailored experience.